Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Tumor DNA in DLBCL patient's stem cells or blood can predict risk of relapse after transplant

Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse. New research led by Dana-Farber Cancer Institute scientists suggests that patients whose blood or stem cell samples harbor tumor DNA are likely to relapse.

8 Dec 2020

Study: CAR T cell therapy is a safe, effective therapy for high-risk large B-cell lymphoma

A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments.

8 Dec 2020

Mice infused with CD5-deleted CAR T cells showed significant reduction in tumor size

Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells' ability to eliminate blood cancers, according to new preclinical data from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center.

8 Dec 2020

CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

7 Dec 2020

Protein interactions could serve as therapeutic targets to treat viral infections

Researchers have investigated the role of the interplays within the proteins membranes of viral families involved in the control of programmed cell death.

30 Nov 2020

Cell survival protein could protect the kidneys from 'bystander' damage during cancer therapy

Australian researchers have identified a protein that could protect the kidneys from 'bystander' damage caused by cancer therapies.

From Walter and Eliza Hall Institute of Medical Research (WEHI) 26 Nov 2020

Scientists identify mechanism involved in new precision cancer drug for blood cancers

University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published today in Nature Communications.

23 Oct 2020

Cell nucleus may enable the cells to evade crowded environments

Like people, cells in the human body protect their personal space. They seem to know how much space they need, and if it gets too tight, most cells prefer to break free.

20 Oct 2020

Researchers discover how specific molecules promote cancer progression

The development of cancer is a highly complicated process, involving multiple genes and signaling pathways that become upregulated or downregulated throughout different stages of tumor growth and spread. Two of the most commonly altered genes in cancer are p53 and AKT.

16 Oct 2020

Immunotherapy using CAR NKT cells shows promise for treating solid tumors

Natural killer T (NKT) cells, a type of immune cells known for their potent anti-cancer properties in murine tumor models, have been developed into a novel form of immunotherapy to treat patients with cancer.

14 Oct 2020

VAV1 gene mutations may promote growth of T-cell tumors in laboratory mice

Life is an exquisite orchestration of growth and change, with checks and balances that fine-tune complex entwined interactions, both intrinsic and external.

13 Oct 2020

New radioimmunotherapy effectively reverses resistance to lymphoma therapy

A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.

9 Oct 2020

CAR T cell therapy can predict treatment outcomes in patients with large B-cell lymphoma

Scientists have identified cellular and molecular features of anti-CD19 CAR T cell infusion products that are correlated with large B-cell lymphoma (LBCL).

6 Oct 2020

Memory training for the immune system

After an infection of the human body with a pathogen, a cascade of reactions will usually be set into motion.

29 Sep 2020

Eliminating tumors with engineered ‘off-the-shelf’ therapeutic T cells

Personalized cancer treatments are no longer just options of the future. In the past few years, researchers have made significant progress in 'teaching' the body's immune T cells to recognize and kill specific cancer cells, and human clinical trials have shown that this approach can successfully eliminate tumors

21 Aug 2020

A genetic link discovered to predict treatment response for patients with rare, aggressive cancer

A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.

13 Aug 2020

Clinical trial shows CAR-T cell therapy can be used for treating Hodgkin lymphoma

CAR-T cell therapy, which attacks cancer cells using a person's reprogrammed immune cells, has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical trial led by researchers at UNC Lineberger Comprehensive Cancer Center and Baylor College of Medicine in Houston.

24 Jul 2020

Lymphoma News and Research

Tumor DNA in DLBCL patient's stem cells or blood can predict risk of relapse after transplant

Study: CAR T cell therapy is a safe, effective therapy for high-risk large B-cell lymphoma

Mice infused with CD5-deleted CAR T cells showed significant reduction in tumor size

CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

Protein interactions could serve as therapeutic targets to treat viral infections

Cell survival protein could protect the kidneys from 'bystander' damage during cancer therapy

Scientists identify mechanism involved in new precision cancer drug for blood cancers

Cell nucleus may enable the cells to evade crowded environments

Researchers discover how specific molecules promote cancer progression

Immunotherapy using CAR NKT cells shows promise for treating solid tumors

VAV1 gene mutations may promote growth of T-cell tumors in laboratory mice

New radioimmunotherapy effectively reverses resistance to lymphoma therapy

CAR T cell therapy can predict treatment outcomes in patients with large B-cell lymphoma

Memory training for the immune system

Eliminating tumors with engineered ‘off-the-shelf’ therapeutic T cells

A genetic link discovered to predict treatment response for patients with rare, aggressive cancer

Clinical trial shows CAR-T cell therapy can be used for treating Hodgkin lymphoma

New approach is more effective in treating certain blood cancers

Reactivating divergent signaling pathways to enhance cancer treatment

Dual inhibitor therapy may be safer for patients with chronic lymphocytic leukemia

Driving Support for Pharmaceutical Testing Through Continuous Innovation

From Memory to Metaplasticity: Unraveling the Brain's Secrets

Revolutionizing Mass Spectrometry: A Deep Dive into Plasmion’s SICRIT® Technology

Latest in Genomics